The Cancer Research Institute of Montpellier U1194 jointly operated by Inserm, University of Montpellier and Institut du Cancer de Montpellier (CLCC) 

220 scientists and support personnel 
17 research teams sharing 5000 m2 of lab space
Excellent core facilities, many being part of the shared facilities network Montpellier BioCampus
Biotech spin-offs 
Ground breaking research in basic and translational oncology developed in close collaboration with clinical departments and clinical research at ICM 
 
One central theme and two unifying programs : Molecular Targets and Cancer Therapy

1. Plasticity of solid tumors : from discoveries to personalized medecine
2. Therapeutic Antibodies in Cancer Treatment : Innovation, design and biological response


Biotechnology

Life Sciences

Research

Therapeutics

IRCM - Institut de Recherche en Cancérologie de Montpellier

Claude Sardet

Alix Bouillin

Thierry Chardès

The Research and Development team at the Institut de Recherche en Cancérologie de Montpellier (IRCM) focuses on pioneering basic and translational oncology research. Comprising senior researchers, postdoctoral scientists, doctoral candidates, and engineers, the team works collaboratively to explore the plasticity of solid tumors and innovate therapeutic antibodies for cancer treatment. Their efforts aim to translate scientific discoveries into personalized medicine and effective therapeutic responses in close coordination with clinical departments and research at ICM.

Research and Development

About

Team members